Cargando…

Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells

Previous studies showed that downregulation of pyrimidine salvage underlies resistance against 5-azacytidine (AZA), indicating an important role for de novo pyrimidine synthesis in AZA resistance. Because de novo pyrimidine synthesis is inhibited by the immunomodulator teriflunomide and its pro-drug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imanishi, Satoshi, Takahashi, Ryoko, Katagiri, Seiichiro, Kobayashi, Chiaki, Umezu, Tomohiro, Ohyashiki, Kazuma, Ohyashiki, Junko H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642525/ https://www.ncbi.nlm.nih.gov/pubmed/29050250 http://dx.doi.org/10.18632/oncotarget.19436

Ejemplares similares

Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells
por: Imanishi, Satoshi, et al.
Publicado: (2018)

Effect of the extracellular component of bone marrow mesenchymal stromal cells from healthy donors on hematologic neoplasms and their angiogenesis
por: Gladkova, Nina, et al.
Publicado: (2020)

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib
por: Ohyashiki, Kazuma, et al.
Publicado: (2016)

A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome
por: Asano, Michiyo, et al.
Publicado: (2019)

Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a
por: Ohyashiki, Junko H, et al.
Publicado: (2010)

Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely
por: Ohyashiki, Junko H, et al.
Publicado: (2014)

Exosomal miRNA Signatures for Late-Onset Acute Graft-Versus-Host Disease in Allogenic Hematopoietic Stem Cell Transplantation
por: Yoshizawa, Seiichiro, et al.
Publicado: (2018)

Development of an Oral Form of Azacytidine: 2′3′5′Triacetyl-5-Azacytidine
por: Ziemba, Amy, et al.
Publicado: (2011)

A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells
por: Ohyashiki, Junko H, et al.
Publicado: (2008)

Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network
por: Gu, Xiaorong, et al.
Publicado: (2020)

Age-related decrease of miRNA-92a levels in human CD8(+ )T-cells correlates with a reduction of naïve T lymphocytes
por: Ohyashiki, Michiyo, et al.
Publicado: (2011)

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population
por: Ohyashiki, Junko H, et al.
Publicado: (2012)

The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5‐azacytidine: Results from the Hellenic 5‐azacytidine registry
por: Diamantopoulos, Panagiotis, et al.
Publicado: (2019)

Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies
por: Xu, Qingyu, et al.
Publicado: (2023)

Cytogenetic effect of 5-azacytidine in patients with hematological malignancies
por: Tsuda, Jessica Romy, et al.
Publicado: (2011)

CNS Involvement in AML Patient Treated with 5-Azacytidine
por: Vasilatou, Diamantina, et al.
Publicado: (2014)

Suppressing nonsense—a surprising function for 5-azacytidine
por: Shao, Ada, et al.
Publicado: (2014)

Clinical Impact of Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma
por: Ohyashiki, Kazuma, et al.
Publicado: (2011)

Azacytidine Treatment for VEXAS Syndrome
por: Raaijmakers, Marc H. G. P., et al.
Publicado: (2021)

Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports
por: Rohon, Peter, et al.
Publicado: (2012)

Effects of 5-Azacytidine on Growth and Hypocrellin Production of Shiraia bambusicola
por: Ma, Yan Jun, et al.
Publicado: (2018)

Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy
por: Xu, Ning, et al.
Publicado: (2021)

5-Azacytidine restores interleukin 6-increased production in mesenchymal stromal cells from myelodysplastic patients
por: Boada, Matilde, et al.
Publicado: (2021)

5-Azacytidine Is Insufficient For Cardiogenesis In Human Adipose-Derived Stem Cells
por: Wan Safwani, Wan Kamarul Zaman, et al.
Publicado: (2012)

5-Azacytidine in Chronic Myelomonocytic Leukemia: Case Report and Review of Literature.
por: Greco, M., et al.
Publicado: (2011)

A Comparative Analysis of 5-Azacytidine- and Zebularine-Induced DNA Demethylation
por: Griffin, Patrick T., et al.
Publicado: (2016)

Synthesis and Antiproliferative Activities of 5-Azacytidine Analogues in Human Leukemia Cells
por: Guo, Gang, et al.
Publicado: (2008)

Effect of the Addition Frequency of 5-Azacytidine in Both Micro- and Macroscale Cultures
por: Kadekar, Sandeep, et al.
Publicado: (2020)

Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes
por: Raj, Kavita, et al.
Publicado: (2006)

Amyloid Angiopathy-related Severe Hemorrhage with Multiple Myeloma
por: Katagiri, Seiichiro, et al.
Publicado: (2017)

Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse
por: Yoshimoto, Takayuki, et al.
Publicado: (2014)

DNA methylation patterns of Brachypodium distachyon chromosomes and their alteration by 5-azacytidine treatment
por: Borowska, Natalia, et al.
Publicado: (2011)

5-azacytidine inhibits nonsense-mediated decay in a MYC-dependent fashion
por: Bhuvanagiri, Madhuri, et al.
Publicado: (2014)

How to Diagnose Early 5-Azacytidine-Induced Pneumonitis: A Case Report
por: Misra, Srimanta Chandra, et al.
Publicado: (2017)

The effects of the DNA Demethylating reagent, 5-azacytidine on SMCHD1 genomic localization
por: Massah, S., et al.
Publicado: (2020)

Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways
por: Minařík, Lubomír, et al.
Publicado: (2022)

NMD inhibition by 5-azacytidine augments presentation of immunogenic frameshift-derived neoepitopes
por: Becker, Jonas P., et al.
Publicado: (2021)

5-Azacytidine-Mediated Modulation of the Immune Microenvironment in Murine Acute Myeloid Leukemia
por: Ebelt, Nancy D., et al.
Publicado: (2022)

Resistance of Leukemia Cells to 5-Azacytidine: Different Responses to the Same Induction Protocol
por: Šimoničová, Kristína, et al.
Publicado: (2023)

Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
por: Okabe, Seiichi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dg664or7lfecjh999o0llt54or